According to IMARC Group, the global real-world evidence solutions market size reached USD 2.0 Billion in 2025 and is projected to reach USD 3.8 Billion by 2034, expanding at a CAGR of 7.01% during 2026-2034. This sustained real-world evidence solutions market growth reflects the rising need for precise, real-world insight into drug safety and efficacy, the expanding role of advanced analytics in clinical development and commercialization, and a broader industry shift from volume-based to value-based care models.

Real-World Evidence Solutions Industry Overview

Real-world evidence refers to clinical evidence regarding the usage, and potential benefits or risks, of a medical product derived from analysis of real-world data. RWE can be generated through a range of study designs, including randomized trials, large simple trials, pragmatic trials, and observational studies. It offers insight into real-world treatment patterns among patient groups covering dosing, compliance, adherence, off-label use, and the balance between efficacy and safety — that clinical trials alone cannot fully capture.

RWE solutions are deployed across a wide continuum of life sciences and healthcare use cases:

  • Regulatory submissions and post-market surveillance: Supporting drug and device approvals, label expansions, and safety monitoring with real-world safety and effectiveness data
  • Health economics and outcomes research (HEOR): Demonstrating comparative effectiveness and value to payers and health technology assessment bodies
  • Clinical trial design and patient identification: Helping researchers identify eligible patient populations and design more representative pre-trial studies
  • Market access and payer negotiations: Providing evidence to support reimbursement decisions and value-based contracting
  • Pharmacovigilance and safety signal detection: Identifying varied adverse reactions and subpopulation effects among complex, comorbid patients

Global Real-World Evidence Solutions Market Size & Key Statistics

Below are the key Real-World Evidence Solutions Market Size statistics drawn from IMARC Group's comprehensive market analysis:

Base Year - 2025

Historical Period - 2020-2025

Forecast Period - 2026-2034

Real-World Evidence Solutions Market Size in 2025 - USD 2.0 Billion

Market Forecast in 2034 - USD 3.8 Billion

Market Growth Rate (2026-2034) - 7.01% CAGR

Largest Region - North America

Leading Component Segment - Clinical Settings Data

Leading Therapeutic Area - Oncology

Leading End-Use Segment - Pharmaceutical and Medical Device Companies

Request for a Sample Report for Detailed Real-World Evidence Solutions Market Share Evaluation: https://www.imarcgroup.com/real-world-evidence-solutions-market/requestsample

Key Market Drivers & Real-World Evidence Solutions Market Trends in 2026

Several powerful forces are shaping Real-World Evidence Solutions Market Trends and fuelling sustained growth expectations across global healthcare and life sciences markets:

1. Rising Demand for Precise Safety and Efficacy Insight

The growing need for accurate, real-world clarity on the safety and efficacy of new drugs and medical products is a central driver of the market. RWE solutions allow manufacturers and regulators to detect varied patient reactions, subpopulation effects, and product value when used by complex and comorbid patients — insight that pivotal clinical trials, with their controlled and narrower populations, cannot fully provide.

2. Expanding Application of Advanced Analytics in Clinical Development

The growing utilization of advanced analytics and technological solutions in RWE for clinical development, commercialization, and accelerating improvements in healthcare outcomes is positively influencing the market. Artificial intelligence, machine learning, and natural language processing are increasingly applied to unstructured EHR and claims data to speed up evidence generation.

3. Government Initiatives Promoting RWE Adoption

Various government initiatives across countries are promoting the use of RWE solutions to evaluate the real-world efficacy of drugs and vaccines. Regulatory frameworks that formally recognize real-world evidence in submission pathways are encouraging broader industry adoption.

4. Shift From Volume-Based to Value-Based Care

The industry-wide shift from volume-based to value-based care is offering lucrative growth opportunities to RWE solution providers, as payers and providers increasingly require outcomes-based evidence to support reimbursement and contracting decisions.

5. Growing Digitalization and Patient-Centered Virtual Care

The growing adoption of digitalization and patient-centered virtual care is catalyzing demand for RWE solutions, as digital health platforms, remote monitoring devices, and telehealth interactions generate continuous streams of real-world patient data.

6. Rising Chronic Disease Burden and Escalating Development Costs

An increase in the global prevalence of chronic diseases such as cancer, obesity, and diabetes, combined with rising delays and costs in drug development, is bolstering demand for RWE solutions that can streamline evidence generation and support faster, more informed development decisions.

Key Market Segmentation

IMARC Group's report categorizes the global real-world evidence solutions market based on component, therapeutic area, end user, and region.

By Component

  • Clinical Settings Data — Largest Segment: Data captured directly within clinical care settings, including electronic health records (EHRs) and hospital information systems, commands the largest component share due to its breadth, clinical granularity, and direct relevance to treatment-pattern analysis.
  • Claims Data: Insurance and administrative claims data provide longitudinal visibility into patient healthcare utilization, costs, and treatment pathways across large populations, making it a critical input for health economics and outcomes research.
  • Patient-Powered Data: Data sourced directly from patients through registries, mobile health apps, and wearable devices is a fast-growing component, offering real-time insight into symptoms, adherence, and quality of life.
  • Pharmacy Data: Prescription and dispensing data support medication adherence analysis, drug utilization studies, and safety monitoring across large patient cohorts.
  • Others: Includes mortality registries, laboratory data, and other supplementary real-world data sources that enrich core RWE datasets.

By Therapeutic Area

  • Oncology — Largest Segment: Oncology exhibits a clear dominance in the therapeutic area segment, driven by the complexity of cancer treatment pathways, the need for long-term outcomes tracking, and the maturity of oncology-specific real-world data networks derived from EHRs and tumor registries.
  • Immunology: Real-world evidence supports comparative effectiveness and long-term safety assessment of biologics and immunotherapies used to treat autoimmune and inflammatory conditions.
  • Neurology: RWE plays a growing role in tracking disease progression and treatment response in chronic neurological conditions where clinical trial populations are often small.
  • Cardiovascular Disease: Real-world data supports post-market surveillance and outcomes research for cardiovascular drugs and devices used across large, diverse patient populations.
  • Others: Includes infectious diseases, rare diseases, respiratory conditions, and additional therapeutic areas increasingly leveraging real-world evidence.

By End User

  • Pharmaceutical and Medical Device Companies — Largest Segment: Pharmaceutical and medical device manufacturers account for the largest end-use share of the Real-World Evidence Solutions Market, leveraging RWE across drug development, regulatory submissions, post-market safety monitoring, and commercialization strategy.
  • Healthcare Payers: Payers use RWE to evaluate comparative effectiveness and cost outcomes, supporting formulary decisions and value-based contracting with manufacturers.
  • Healthcare Providers: Hospitals and health systems apply real-world evidence to guide clinical decision-making, quality improvement initiatives, and population health management.
  • Others: Includes academic and research institutions, government agencies, and health technology assessment bodies utilizing RWE for policy and research purposes.

Regional Real-World Evidence Solutions Market Analysis

North America — Largest (United States, Canada )

Advanced healthcare data infrastructure, high EHR adoption, strong regulatory recognition of RWE in FDA submission pathways, and concentration of leading RWE solution providers

Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Others

Growing use of RWE in health technology assessment and reimbursement decisions, expanding national health data registries, and increasing pharmaceutical R&D collaboration

Asia-Pacific: China, Japan, India, South Korea, Australia, Indonesia, Others

Rapid healthcare digitalization, expanding EHR infrastructure, growing chronic disease burden, and rising government support for real-world data initiatives

Latin America: Brazil, Mexico, Others

Expanding private healthcare data adoption and growing pharmaceutical industry interest in real-world outcomes research

Middle East and Africa: Gradual healthcare digitalization and rising interest in real-world data to support regional public health and market access decisions

North America leads the global Real-World Evidence Solutions Market Share, supported by mature electronic health record infrastructure, strong regulatory frameworks that formally recognize real-world evidence in submission pathways, and a dense concentration of established RWE solution providers headquartered in the region.

Connect for Detailed Real-World Evidence Solutions Market Share Segmentation Analysis — Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=6149&flag=C

Leading Players in the Global Real-World Evidence Solutions Industry

The report provides a comprehensive analysis of the competitive landscape in the global real-world evidence solutions market, with detailed profiles of all major companies, including:

  • Aetion Inc.
  • Clinigen Limited
  • Flatiron Health
  • ICON plc
  • IQVIA Inc.
  • Optum, Inc.
  • Oracle Corporation
  • Parexel International (MA) Corporation
  • SAS Institute Inc.
  • Syneos Health
  • Thermo Fisher Scientific Inc.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Healthcare, Technology, Chemicals, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

 

United Kingdom: +44-753-714-6104